Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 72Lymphoma 63Lymphoma, Follicular 59Lymphoma, Mantle-Cell 58Lymphoma, Large B-Cell, Diffuse 40Multiple Myeloma 36Hodgkin Disease 32Recurrence 29Lymphoma, B-Cell, Marginal Zone 28Lymphoma, B-Cell 19Leukemia 18Waldenstrom Macroglobulinemia 14Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasms, Plasma Cell 8Lymphoma, T-Cell 7Leukemia, Myeloid, Acute 7Burkitt Lymphoma 7Lymphoma, T-Cell, Peripheral 6Leukemia, B-Cell 6Hematologic Neoplasms 6Sezary Syndrome 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Immune System Diseases 5Small Cell Lung Carcinoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

Dexamethasone 10fludarabine phosphate 9Melphalan 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 7Cyclophosphamide 7Mycophenolic Acid 6Bortezomib 6Tacrolimus 5Calcium Dobesilate 4filanesib 3dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3carfilzomib 3auricularum 3Stem Cell Transplantation 3Sirolimus 3Filgrastim 3liposomal doxorubicin 2ixazomib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × Bendamustine Hydrochloride × Clear all
NCT02315157 2025-10-15

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Thomas Jefferson University

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡